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8 The Journal of Thoracic and Cardiovbjective: The study sought to determine whether citrulline supplementation, a
recursor to nitric oxide synthesis, is safe and efficacious in increasing plasma
itrulline concentrations and decreasing the risk of postoperative pulmonary hyper-
ension.
tudy Design: Forty children, undergoing cardiopulmonary bypass and at risk for
ulmonary hypertension, were randomized to receive 5 perioperative doses (1.9
/m2 per dose) of either oral citrulline or placebo. Plasma citrulline and arginine
oncentrations were measured at 5 time points. Measurements of systemic blood
ressure and presence of pulmonary hypertension were collected.
esults: Median citrulline concentrations were significantly higher in the citrulline
roup versus the placebo group immediately postoperatively (36 mol/L vs 26
mol/L, P  .012) and at 12 hours postoperatively (37 mol/L vs 20 mol/L, P 
015). Mean plasma arginine concentrations were significantly higher in the citrul-
ine group versus the placebo group by 12 hours postoperatively (36 mol/L vs 23
mol/L, P .037). Mean systemic blood pressure did not differ between groups (P
53). Postoperative pulmonary hypertension developed in 9 patients, 6 of 20 (30%)
n the placebo group and 3 of 20 (15%) in the citrulline group (P  .451), all of
hom had plasma citrulline concentrations less than age-specific norms. Postoper-
tive pulmonary hypertension did not develop in patients who demonstrated plasma
itrulline concentrations in excess of 37 mol/L (P  .036).
onclusions: Oral citrulline supplementation safely increased plasma citrulline and
rginine concentrations compared with placebo after cardiopulmonary bypass. Post-
perative pulmonary hypertension did not occur in children with naturally elevated
itrulline levels or elevations through supplementation. Oral citrulline supplemen-
ation may be effective in reducing postoperative pulmonary hypertension.
ulmonary hypertension is a potentially severe complication after conge
heart surgery that can lead to right-ventricular failure, reduced cardiac output,
and death.1 Treatment options include oxygen administration, induced al
osis, sedation, paralysis, inotropic support, and parenteral or inhaled vasodila2
Nitric oxide (NO) causes cyclic guanosine monophosphate-mediated vasodila-
ion of the pulmonary vasculature. Endogenous NO is produced from the metabo-
ism of citrulline and L-arginine, amino acids generated by the urea cycle 
).3 Cardiopulmonary bypass leads to significant reductions in postoperative con
rations of citrulline and arginine,4 and dysfunction of the pulmonary endothelium.5,6
Intravenous L-arginine has been shown to reduce both pulmonary and systemic
ressures.5,7 This global response would not be tolerated in patients after c
urgery, who are already prone to low cardiac output states. The maintenance of
igh plasma arginine concentrations is also problematic because of poor bioavail-
ascular Surgery ● July 2006
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Dbility and swift metabolism by intestinal and cytosolic
rginase.8 In contrast, administration of oral citrulline
ore effective in maintaining plasma L-arginine concentra-
ions than administration of arginine in healthy voluntee9
itrulline has no recognized toxicity and is used as replace-
ent therapy for children with urea cycle defects.
The purpose of this study is to determine whether peri-
perative oral citrulline supplementation is (1) safe in pa-
ients after heart surgery, (2) efficacious in increasing plasma
itrulline and arginine concentrations, and (3) associated with
evelopment of postoperative pulmonary hypertension.
ethods
atient Enrollment
anderbilt Institutional Review Board approval was obtained be-
ore patient enrollment. Forty patients were prospectively enrolled
n this randomized, placebo-controlled, doubled-blinded study at
anderbilt Children’s Hospital between April 2003 and September
004.
All infants or children less than 6 years of age undergoing 1 of
surgical procedures for correction of congenital heart lesions
ere eligible for enrollment. Procedures included (1) ventricular
eptal defect repair, (2) atrioventricular septal defect repair, (3)
idirectional Glenn procedure, (4) modified Fontan procedure, (5)
orwood I procedure with right ventricle to pulmonary artery
onduit for hypoplastic left heart syndrome, and (5) arterial switch
rocedure for transposition of the great arteries. Exclusion criteria
ncluded (1) significant pulmonary artery narrowing not addressed
urgically, (2) previous pulmonary artery stent placement, (3)
revious pulmonary artery angioplasty, (4) significant left-sided
trioventricular valve regurgitation, (5) pulmonary venous return
bnormalities, and (6) pulmonary vein stenosis.
Informed written consent was obtained from parents at the
reoperative evaluation. One of 3 cardiac surgeons at Vanderbilt
hildren’s Hospital performed the surgical procedures using sim-
lar cardiopulmonary bypass and cardioplegia preparations.
Pulmonary hypertension was defined as mean pulmonary arte-
ial pressures of at least 25 mm Hg or exceeding 50% of the mean
ystemic artery pressure.10,11
Pulmonary pressures were also estimated by Doppler echocar-
iography with the following diagnostic criteria: (1) significant
ricuspid regurgitation, (2) enlarged or hypertrophied right ventri-
le without evidence of pulmonary stenosis, or (3) intraventricular
eptal flattening.12,13
All patients underwent perioperative and postoperative trans-
sophageal echocardiograms per cardiac intensive care protocol.
n addition, patients without direct pulmonary arterial monitoring
nderwent subsequent echocardiograms in the 48-hour postoper-
Abbreviations and Acronyms
IQR  interquartile range
NO  nitric oxide
PCCU pediatric critical care unittive period when clinically indicated for pulmonary hypertension. m
The Journal of Thoracchocardiograms were not obtained for pulmonary pressure deter-
ination in patients undergoing the modified Fontan or bidirectional
lenn procedures. Perioperative or postoperative transesophageal or
ransthoracic echocardiograms were interpreted by pediatric cardiol-
gists at Vanderbilt Children’s Hospital.
Physicians, nursing staff, and patients/families were blinded to
reatment arm assignments. Clinical data and patient demographics
ere obtained from medical records before knowledge of study
esults.
dverse Event
ystemic blood pressure was monitored continuously during the
8-hour study period because of the theoretic risk of hypotension
ssociated with citrulline administration. An adverse event was
efined as a greater than 25% decrease in systemic mean blood
ressure from baseline (measured before cardiopulmonary by-
ass). Hypotensive patients were treated with volume resuscitation
nd/or pharmacologic support. Patients were not withdrawn from
he study unless hypotension was unresponsive to interventions.
tudy Protocol
orty patients were randomized to receive either placebo or
itrulline perioperatively. Randomization was performed by the
nvestigational Drug Service of the Vanderbilt Hospital Clinical
harmacy using computer-generated random numbers in permuted
locks of 4. Patients were enrolled with the intention-to-treat
igure 1. Urea cycle enzymes are differentially found in 2 com-
artments: the mitochondria of hepatocytes and the cytosol of all
ells. Citrulline easily moves across cellular membranes. Once
ithin the cytosol, citrulline is metabolized into L-arginine,
hich is then metabolized either by arginase into urea or by nitric
xide synthetase into NO. ATP, Adenosine triphosphate; CPSI,
arbamoyl phosphate synthetase I; OTC, ornithine transcarbamy-
ase; ARG, arginine; NOS, nitric oxide synthetase; NO, nitric
xide; ASS, argininosuccinate synthetase; ASL, argininosucci-
ate lyase.odel.
ic and Cardiovascular Surgery ● Volume 132, Number 1 59
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DCitrulline was administered as a 100 mg/mL (10%) solution
ith distilled water as a suspending agent. The drug and placebo
ere mixed and distributed by the Investigational Drug Service.
itrulline and placebo were matched for volume and color. Cit-
ulline was administered in 5 doses of 1.9 g/m2 given every 12
ours for a daily dose of 3.8 g/m2 and for a total dose of 9.5 g/m2.
his dose was determined by current citrulline replacement ther-
py for infants and children with urea cycle defects.14,15
The first dose of placebo/citrulline was administered through an
rogastric feeding tube placed by the research nurse or physician
fter induction of anesthesia and intubation but before cardiopul-
onary bypass in the operating room. The second dose was given
mmediately on arrival in the pediatric critical care unit (PCCU)
or recovery. The third, fourth, and fifth doses were administered
t 12, 24, and 36 hours postoperatively in the PCCU, respectively.
ostoperative doses were given enterally through a nasogastric
eeding tube positioned by the bedside nurse in the PCCU, or by
outh once the patient was extubated.
ample Collection
hree milliliters of blood were obtained from each patient at 5 time
oints: immediately before and after bypass, and at 12, 24, and 48
ours postoperatively. The preoperative blood sample was col-
ected after both anesthetic induction and placement of an arterial
r a central venous catheter but before surgical incision and study
rug administration. The immediate postoperative sample was
ollected on arrival in the PCCU, and subsequent samples were
ollected at respective time intervals and before study drug admin-
stration. Samples were collected in citrated tubes, placed on ice,
nd stored at 4°C until processing. Samples were centrifuged
ithin 3 hours of collection for separation of plasma and cellular
omponents. Plasma samples were frozen at 70°C until further
aboratory analysis.
Patients were monitored in the PCCU during drug administra-
ion and blood collection up to 48 hours postoperatively. If patients
ad successful recovery before 48 hours with transfer out of the
CCU, central and arterial lines were removed, and therefore drug
dministration and blood collection were concluded.
aboratory Measurements
oncentrations of plasma citrulline, arginine, and all other amino
cids were determined by amino-acid analysis on protein-free
xtracts. Amino acids were separated by cation-exchange chroma-
ography using a Hitachi L8800 amino acid analyzer (Hitachi
SA, San Jose, Calif). Calibration of the analyzer was completed
efore testing of patient samples.
tatistical Analysis
ontinuous outcome variables, when not normally distributed,
ere reported as medians with interquartile range (IQR). The
hapiro-Wilk test assessed normality. The Mann-Whitney U and
ilcoxon signed-rank tests compared unpaired and paired contin-
ous variables not normally distributed between groups. Dichoto-
ous outcomes for success of randomization and the presence of
ulmonary hypertension were reported as proportions and assessed
ith the Fisher exact test. Parametric testing was used when data
ere normally distributed and reported as means  standard
eviation. Analysis of covariance assessed differences between o
0 The Journal of Thoracic and Cardiovascular Surgery ● July 2roups in repeated measurements of systemic mean blood pres-
ure. All analyses were 2-sided. Statistical analysis was performed
ith STATA software, version 8.0 (College Station, Tex).
The power calculation for this study was based on the previously
eported mean citrulline concentration of 20.7  13.0 mol/L in
hildren after cardiopulmonary bypass.4 A sample size of 4
atients equally distributed would have a power (1-) of 87% to
etect a 13 mol/L (1 standard deviation) difference between oral
itrulline (n 20) and placebo (n 20) using 2-sided significance
nd an   0.05.
esults
atient Enrollment
orty patients were randomized to receive citrulline (n 
0) or placebo (n  20). Baseline characteristics between
he 2 groups are shown in Table 1. The median age 
tudy population (N  40) was 8.5 months (IQR 4-29
onths); 55% were male, and 90% were white. Surgical
nterventions included ventriculoseptal defect or atrioven-
ricular septal defect repair (25%), bidirectional Glenn or
ontan procedures (53%), arterial switch repair for transpo-
ition of the great arteries (15%), and Norwood stage I
epair (8%).
afety
ean blood pressure did not differ between the citrulline
nd placebo groups (P  .530) (Figure 2). No deat
ccurred within the 48-hour study period. Three patients died
ABLE 1. Demographic characteristics between groups
Placebo
(n  20)
Citrulline
(n  20) P-value
ge-months (median, IQR) 8 (4-29) 12 (0.3-29) .892
ender .751
Male 12 (60%) 10 (50%)
Female 8 (40%) 10 (50%)
thnicity 1.000
Caucasian 18 (90%) 18 (90%)
Non-Caucasian 2 (10%) 2 (10%)
iagnosis .901
Single ventricle 11 (55%) 13 (65%)
VSD/AVSD 6 (30%) 4 (20%)
TGA 3 (15%) 3 (15%)
urgery .452
BDG/Fontan 11 (55%) 3 (15%)
VSD/AVSD 6 (30%) 10 (50%)
Arterial switch 3 (15%) 4 (20%)
Norwood 0 (0%) 3 (15%)
risomy 21 .661
Present 4 (20%) 2 (10%)
Absent 16 (80%) 18 (90%)
ypass time-minutes
(mean  SD)
112  42 121  47 .520f postoperative complications within 30 days of surgical re-
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Dair (2 in the citrulline group vs 1 in the placebo group). All
eaths were reported to the institutional review board and were
ound to be unrelated to study drug administration.
All patients (N  40) completed the study protocol
hrough 12 hours postoperatively. Nine children (4/20 in the
itrulline group and 5/20 in the placebo group) successfully
ecovered by 24 hours postoperatively and transferred out of
he PCCU, at which time the study concluded for those
ndividual patients. One patient in the oral citrulline group
as withdrawn at 4 hours postoperatively because of com-
lications requiring further surgical intervention, although
onitoring continued through 48 hours postoperatively.
hese patients were represented in all analyses when appro-
riate through 12 hours postoperatively.
lasma Citrulline Concentrations
edian plasma citrulline concentrations were no different
etween groups at baseline (P  .355). After citrulline
upplementation, plasma citrulline concentrations were sig-
ificantly higher in the oral citrulline group when compared
ith placebo immediately postoperatively (36 mol/L IQR
8-48 mol/L vs 26 mol/L IQR 24-35 mol/L, P  .012)
nd 12 hours postoperatively (37 mol/L IQR 18-83
mol/L vs 20 mol/L IQR 15-29 mol/L, P  .015)
Figure 3). The placebo group demonstrated a signifi
ecrease from baseline in plasma citrulline concentrations
fter cardiopulmonary bypass immediate postoperatively
nd 12 hours postoperatively (32 mol/L IQR 25-44
mol/L vs 26 mol/L and 20 mol/L, P  .020 and P 
001, respectively). In contrast, the oral citrulline group
igure 2. Mean blood pressure did not differ between the oral
itrulline and placebo groups (P  .53, multivariate analysis of
ovariance) throughout the 48-hour study period. Means  stan-
ard deviation are shown for each group.emonstrated a significant increase from baseline in plasma p
The Journal of Thoracitrulline concentrations by 12 hours postoperatively (29
mol/L IQR 25-34 mol/L vs 36 mol/L, P  .014).
lasma Arginine Concentrations
ean plasma arginine concentrations were no different be-
ween groups at baseline (P  .495). After citrulline supple-
entation, plasma arginine concentrations were significantly
igher in the oral citrulline group compared with the placebo
roup by 12 hours postoperatively (36  24 mol/L vs 23 
3 mol/L, P  .037) (Figure 4). The placebo group dem
trated a significant decrease from baseline in plasma arginine
oncentrations by 12 hours postoperatively (38 mol/L IQR
0-52 mol/L vs 23 mol/L, P  .001). In contrast, the oral
itrulline group maintained postoperative plasma arginine
oncentrations at baseline through 12 hours postoperatively
33 mol/L IQR 25-54 mol/L vs 36 mol/L, P  .533).
ulmonary Hypertension
wenty-eight patients had direct pulmonary arterial pressure
easurements (Table 2), of whom 13 of 28 (46%) were 
itrulline group. Pulmonary pressures trended lower in the
itrulline group compared with placebo immediately post-
peratively (18  5 vs 20  4, P  .127), 6 hours postop-
ratively (17  5 vs 18  4, P  .290), and 12 hours
ostoperatively (17  6 vs 17  5, P  .486), although
tatistical significance could not be demonstrated in this
ilot study.
Postoperative pulmonary hypertension developed in 9
igure 3. Median plasma citrulline concentrations were signifi-
antly higher in the oral citrulline group when compared with the
lacebo group immediately postoperatively (P  .012) and 12
ours postoperatively (P  .015). The placebo group demon-
trated a decrease in citrulline concentrations immediately post-
peratively and 12 hours postoperatively (P  .020, P  .001).
edians and 95% confidence intervals are shown for each group.atients, 6 of 20 (30%) in the placebo group and 3 of 20
ic and Cardiovascular Surgery ● Volume 132, Number 1 61
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D15%) in the citrulline group (P  .451), all of whom had
lasma citrulline concentrations less than age-specific norms
or children aged less than 6 years (30 mol/L IQR 23-37
mol/L).16 The surgical interventions of these 9 patie
ncluded ventriculoseptal defect repair (2/9), atrioven-
riculoseptal defect repair (1/9), arterial switch repair
3/9), Glenn procedure (1/9), and Fontan procedure (2/9).
atients with pulmonary hypertension had significantly
onger cardiopulmonary bypass runs (P  .04), signifi-
antly longer crossclamp times (P  .034), and signifi-
antly more postoperative blood loss (P  .001) when
ompared with the study population. Postoperative pul-
onary hypertension did not develop in patients with
lasma citrulline concentrations in excess of 37 mol/L
 P  .036, Table 3).
The mean arginine concentrations were no different be-
ween patients with pulmonary hypertension receiving cit-
ulline compared with placebo immediately postoperatively
28 18 mol/L vs 35 15 mol/L, P  .269) or at other
ime points. Although the mean citrulline concentrations
ere significantly higher in patients with pulmonary hyper-
ension receiving citrulline compared with placebo imme-
iately postoperatively (42 21 mol/L vs 21 8 mol/L,
 .025), concentrations were not significantly different at
ther time points (Table 4).
iscussion
e found that oral citrulline supplementation safely in-
igure 4. Mean plasma arginine concentrations were signifi-
antly higher in the oral citrulline group when compared with the
lacebo group by 12 hours postoperatively (P  .037). The pla-
ebo group demonstrated a decrease in plasma arginine concen-
rations by 12 hours postoperatively (P < .001). Means and stan-
ard error of mean are shown for each group.reased postoperative plasma citrulline and arginine con- f
2 The Journal of Thoracic and Cardiovascular Surgery ● July 2entrations compared with placebo in children after congen-
tal heart surgery. Mean systemic blood pressure was not
ifferent between the oral citrulline and placebo groups,
espite significantly different plasma citrulline concentra-
ions. Furthermore, increased plasma citrulline concentra-
ions were associated with a decreased risk of postoperative
ulmonary hypertension.
Pulmonary hypertension can be a significant complica-
ion in children after surgical correction of their congenital
eart lesions.4 Rescue therapy of postoperative pulmona
ypertension is limited to inhaled NO. Although efficacious,
O is expensive, restricted to inhaled administration, and
omplicated by rebound pulmonary hypertension after dis-
ontinuation.17 Developments of other therapies such 
itrulline supplementation that are safe, inexpensive, and
asy to administer will potentially improve postoperative
utcomes.
The surgical interventions required for correction of con-
enital heart defects impair the production of endogenous
O, which disables pulmonary vascular homeostasis. Car-
iopulmonary bypass causes pulmonary endothelial dys-
unction through reduction of citrulline and arginine sub-
trate, injury to cells secondary to complement activation
nd effects of oxygen free-radicals, and activation of NO
ynthase antagonists.5,6,18 We previously showed that ca-
iopulmonary bypass leads to significant decreases in both
itrulline and arginine concentrations postoperatively, which
o not return t o baseline even by 48 hours postoperativel4
he inability to produce endogenous NO secondary to cit-
ulline and arginine losses in addition to dysfunction of the
ulmonary endothelium may exacerbate the risk of postop-
rative pulmonary hypertension.
Increased pulmonary blood flow, observed with transpo-
ition of the great arteries and ventriculoseptal defects,
romotes development of pulmonary hypertension through
tructural and functional abnormalities in the pulmonary vas-
ulature.19 Other surgical interventions such as the Fontan 
idirectional Glenn procedures rely heavily on low pulmo-
ary pressures for passive pulmonary blood flow. Both the
ustained increased preoperative pulmonary blood flow and
he deleterious effects of cardiopulmonary bypass are major
ontributors to the development of postoperative pulmonary
ypertension.5
The expected significant decrease in plasma citrulline
nd arginine concentrations after cardiopulmonary bypass
as prevented with the administration of oral citrulline.
his effect may be secondary to both continuous production
f L-arginine from citrulline and stimulation of the NO
athway in both hepatic and pulmonary tissues. Oral citrul-
ine exhibits good bioavailability with ease of movement
cross cellular membranes. The cytosolic portion of the urea
ycle enables localized, intracellular production of L-arginine
rom citrulline within the pulmonary endothelium.20 The
006
l
o
i
s
t
d
e
d
e
a
t
L
a
r
p
s
N
l
h
p
c
r
p
T
C
B
d
c
p
d
T
p
P
p
Smith et al Surgery for Congenital Heart Disease
CH
Docal production of NO may be inferred from the association
f high plasma citrulline concentrations and the decreased
ncidence of pulmonary hypertension without coexisting
ystemic hypotension as suggested by this study.
The risk and severity of postoperative pulmonary hyper-
ension may vary on the basis of the type of congenital heart
efect or surgical intervention required. We did not restrict
ABLE 2. Patients with pulmonary artery pressure measur
ase Citrulline Procedure
Presence
of PHTN Postoperative
4 0 BDG/Fontan No 19
6 0 BDG/Fontan No 15
8 0 BDG/Fontan No 12
11 0 BDG/Fontan Yes 20
15 0 BDG/Fontan No 19
24 0 BDG/Fontan No 17
27 0 BDG/Fontan No 18
28 0 BDG/Fontan No 19
29 0 BDG/Fontan No 26
37 0 BDG/Fontan No 18
40 0 BDG/Fontan No 18
10 0 VSD/AVSD No 25
16 0 VSD/AVSD Yes 22
35 0 VSD/AVSD Yes 25
2 0 Switch Yes 23
1 1 BDG/Fontan No 12
5 1 BDG/Fontan No 16
7 1 BDG/Fontan Yes 21
9 1 BDG/Fontan No 22
13 1 BDG/Fontan No 16
14 1 BDG/Fontan No 6
25 1 BDG/Fontan No 24
26 1 BDG/Fontan No 16
38 1 BDG/Fontan No 17
39 1 BDG/Fontan Yes 19
20 1 VSD/AVSD No 21
21 1 VSD/AVSD No 17
3 1 Switch Yes 24
DG, Bidirectional Glenn; VSD, ventriculoseptal defect; AVSD, atrioventricu
efined as mean pulmonary arterial pressures (MPAP) of at least 25 mmHg
itrulline group had PA pressures which trended lower than the place
ostoperative (17  5 vs 18  4, P  .290), and 12-hours postoperative
emonstrated in this pilot study.
ABLE 3. Low risk of pulmonary hypertension with high
lasma citrulline
lasma citrulline 12 h
ostoperatively
Pulmonary
hypertension
absent
Pulmonary
hypertension
present P value
37 mol/L 18 9
37 mol/L 12 *0 .036nrollment to a single cardiac lesion/surgical intervention, a
The Journal of Thoracespite the possible concern for confounders. Restricting
nrollment to a homogenous population would not have
ppropriately addressed the treatment issues associated with
he complicated disease process of pulmonary hypertension.
arger intervention trials can stratify randomization by di-
gnosis that may decrease concern for confounders. We
andomized patients equally between the oral citrulline and
lacebo groups without stratification because of the small
ample size. Consequently, all 3 patients undergoing the
orwood I procedure were randomly assigned to the citrul-
ine group. This imbalance had a risk of favoring the null
ypothesis because these patients historically have more com-
licated postoperative courses associated with extremely low
ardiac output states. However, these patients demonstrated a
elatively uncomplicated 48-hour postoperative course, which
resumably permitted adequate absorption of citrulline and
nts after bypass, placebo (cit  0) and citrulline (cit  1)
Pulmonary arterial pressures (mm Hg)
6 h 12 h 18 h 24 h 30 h 46 h 42 h 48 h
12 15 16
19 17 17 16 18 17 19 19
15 9 12 18
16 15 20 18 20 19 17 20
17 15 17 17 18 16 17 14
18 17 25 21
19 14 13 11 11 8
15 15 18 13 13 16 17
19 15 21 15 18 19 22 21
19 17 18 18 18 18 22 18
12
16 21 21 19 23 28 19 26
26
27 31 32 29 31 30 34 30
10 9 10 9
17 10 14 16 11 2 11
19 22 29 22 27 22 35 30
15 18 18 21 16 12 14
13 12 9 12
13 17 6
9 17 15 15 14 17 15 19
16 12
16 15 17
25 31 22 20 20 23 23 21
20 17
22 18 20
24 20 25 25 23 23 29 28
ptal defect; PHTN, pulmonary hypertension. Pulmonary hypertension was
/or exceeding 50% of the mean systemic artery pressure (MSAP).10,11 The
oup immediately postoperative (18  5 vs 20  4, P  .127), 6-hours
6 vs 17  5, P  .486), although statistical significance could not beeme
lar se
 and
bo gr
(17 ppropriate assessment of its clinical effects.
ic and Cardiovascular Surgery ● Volume 132, Number 1 63
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DThis pilot study demonstrated that an oral citrulline reg-
men used in children with urea cycle defects can also be
afely administered to children undergoing cardiopulmo-
ary bypass with subsequent elevations in plasma citrulline
oncentrations. We were able to further demonstrate an
ssociation between citrulline concentrations and occur-
ence of postoperative pulmonary hypertension. Two limi-
ations in definitively describing this relationship included
he method of pulmonary hypertension diagnosis and the
itrulline-dosing regimen. Our study protocol limited inter-
erence of routine postoperative care, and therefore pulmo-
ary arterial lines were not mandated. Diagnosis of postop-
rative pulmonary hypertension in patients without direct
ulmonary pressure measurement was completed by echo-
ardiography, which has known limitations.
Few patients receiving oral citrulline did not demonstrate
he significant increase in plasma citrulline concentration,
nd consequently were at risk for postoperative pulmonary
ypertension. Risk factors for development of pulmonary
ypertension in this study population included significantly
onger cardiopulmonary bypass runs, longer crossclamp
imes, and more postoperative blood loss. Inability to over-
ome pulmonary endothelial dysfunction because of ongo-
ng citrulline losses after bypass may have exacerbated the
isk of developing pulmonary hypertension in these pa-
ients. We expect that higher doses of oral citrulline will
chieve levels in much greater excess than 37 mol/L, and
hat with consistently elevated citrulline concentrations pul-
onary hypertension may be prevented. With this pilot
tudy, we targeted those plasma concentrations that are
ssociated with a decreased risk of pulmonary hypertension.
urthermore, the safety data and plasma concentrations
ABLE 4. Characteristics of patients with pulmonary hype
ase Citrulline Age Procedure
Method of
PHTN
diagnosis
Echo PAP Pre
2 Placebo 1 mo Switch Yes 104
31 Placebo 1 mo Switch Yes 56
16 Placebo 4 mo AVSD Yes 39
35 Placebo 5 mo VSD Yes 70
36 Placebo 8 mo VSD Yes 22
11 Placebo 8 mo BDG Yes 30
3 Citrulline 1 mo Switch Yes 24
7 Citrulline 29 mo Fontan Yes 57
39 Citrulline 25 mo Fontan Yes 33
HTN, Pulmonary hypertension; Echo, echocardiography; PAP, pulmon
oseptal defect; BDG, bidirectional Glenn. The median citrulline conc
mmediately postoperative (36 umol/L vs 26 umol/L, P  .012) and at 12-h
itrulline concentrations in excess of 37 umol/L, whether naturally o
ulmonary hypertension (P  .036).chieved with oral citrulline enabled us to begin pharmaco-
4 The Journal of Thoracic and Cardiovascular Surgery ● July 2inetic studies of intravenous citrulline and its future use in
he treatment of pulmonary hypertension.
onclusion
ral citrulline supplementation safely increased plasma
oncentrations of both citrulline and arginine compared
ith placebo. Elevations in plasma citrulline concentrations
bove age-specific norms, whether naturally occurring or
ith citrulline supplementation, were associated with a de-
reased risk of postoperative pulmonary hypertension. There-
ore, aggressive oral citrulline supplementation or future use
f intravenous citrulline, resulting in consistent citrulline
oncentrations in excess of 37 mol/L, may prevent post-
perative pulmonary hypertension.7
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